ABC News: What you need to consider if you’re planning to travel overseas with your unvaccinated kids

With international borders now open in New South Wales, Victoria and the ACT, experts are urging people to plan trips carefully, especially when accompanied by unvaccinated children.  

डॉ डेरिल चेंगFellow at the Department of Paediatrics at the University of Melbourne shares his key recommendations for parents travelling overseas with unvaccinated kids, including weighing up the risks and benefits, and the importance of being well prepared and familiar with local health systems in their travel destinations. 

पूरा लेख पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
What you need to consider if you’re planning to travel overseas with your unvaccinated kids

Omicron variant: will the COVID-19 Pfizer, Moderna, AstraZeneca vaccines protect you?

Scientists around the world are looking at whether protective antibodies in the current COVID-19 vaccines are “sufficiently high” to cover the new Omicron strain. Additionally, the WHO and governments are assessing the severity of the new variant. 

Vaccine makers, including Pfizer and Moderna have been working on “next-generation” mRNA vaccines that would be able to target particular variants circulating. Current data suggests that the COVID-19 vaccines used in Australia will protect against severe disease. 

To read the full article, please click on the link below:

Omicron variant: will the COVID-19 Pfizer, Moderna, AstraZeneca vaccines protect you? 

Moderna says new vaccine for Omicron variant may be ready in early 2022

Moderna Inc. Chief Medical Officer Paul Burton has announced that they are working rapidly to test the current vaccine against the Omicron variant and studying two booster candidates. 

Current data suggests that protection against the new strain still exists, depending on the length of time passed from an individual's second vaccine dose. 

To read the full article, please follow the link below:

Moderna says new vaccine for Omicron variant may be ready in early 2022  


New educational resource: Generation Next course on COVID and kids

MVEC has collaborated with the team at Generation Next on a new resource featuring Dr Daryl Cheng to provide helpful strategies to get kids back to school safely and reduce transmission of COVID-19 in this group.

Course content reflects the combined efforts of immunisation paediatricians, adult physicians, immunisation nurses, infectious disease, and allergy specialists, as well as infection control teams. The information works to provide guidance and support for parents and communities to ensure a safe transition to a new COVID normal.

To enrol in this free course, please click on the link below:

Next Generation course: Covid and kids

Final episode of COVID19 Road to a vaccine: Professor Walter Orenstein

In the final episode of this podcast series our host, Associate Professor Nigel Crawford, speaks with Professor Walter Orenstein. Dr Orenstein is a Professor of Medicine, Epidemiology, Global Health and Paediatrics at Emory University; Associate Director of the Emory Vaccine Center and the Director of Emory Vaccine Policy and Development. An expert in vaccinology, Dr Orenstein has worked at the US Centers for Disease Control and Prevention, Director of the United States Immunisation Program and is a current member of several WHO groups. Further to this he is the co-editor of the vaccine textbook, Plotkin’s Vaccines, 7वां edition. In this episode they discuss:

  • Lessons that can be learnt from Plotkin’s Vaccines in the setting of the SARS-CoV-2 pandemic and development of vaccines
  • Recent press releases showing promising early results from two mRNA COVID-19 vaccine candidates developed by Pfizer/BioNTech and Moderna
  • The critical role of ongoing monitoring for safety and effectiveness of vaccines once they are in use
  • The likely highest priority groups when vaccines do become available
  • The role of children in SARS-CoV-2 transmission and whether or not they need to be vaccinated
  • The importance of a correlate of protection in SARS-CoV-2 vaccines
  • The need to monitor for vaccine associated enhanced disease (VAED)
  • The importance of immunisation providers supporting reports of adverse events following immunisation (AEFI)
  • The importance of communication in supporting vaccine acceptance and uptake
  • Key next steps on the road to a COVID-19 vaccine: a better understanding of how many doses are required and when, a prioritisation process so the vaccines can be used most effectively (with a clear allocation system); and communicating to the public that social distancing and wearing a mask will be ongoing for some time as a level of normality won’t be reached immediately, even with the exciting new efficacious COVID-19 vaccines


आप यहां एपिसोड सुन सकते हैं:

स्प्रेकर - सेब - Spotify

The Conversation: Moderna’s COVID vaccine reports 95% efficacy

The American biotech company Moderna has released early data from phase III clinical trials, announcing that its COVID-19 vaccine has an efficacy level of 94.5%.

Like Pfizer's vaccine, the Moderna vaccine is also an mRNA (messenger RNA) vaccine, however will be easier to distribute as its temperature requirements are 4℃ for 30 days (rather than -70℃ as in the case of the Pfizer vaccine); and for storage requirements beyond 30 days it needs to be kept at -20℃.

The stage III trial involved 30,000 participants, out of those 95 people developed COVID-19 in the week after the final vaccination, with 90 of those being in the placebo group and only 5 in the group who received the COVID vaccine.

It is unknown how long protection from this vaccine lasts and how effective it is in the elderly, pregnant women or those with a chronic illness; however, in results Moderna published in September the vaccine produced a similar amount of antibodies in adults over 70 as adults under 70 years of age. It did however induce fewer T cells in people aged over 71, so at this stage it is not know whether this will result in lower protection or shorter lasting immunity in the elderly.

नीचे दिए गए लिंक के माध्यम से और पढ़ें:

COVID19 रोड टू ए वैक्सीन एपिसोड 17: कैसे COVID-19 महामारी का प्रबंधन ब्रिटिश कोलंबिया, कनाडा में डॉ बोनी हेनरी के साथ किया जा रहा है

हमारे COVID19 रोड टू ए वैक्सीन सीरीज़ के एपिसोड 17 में, हमारे मेजबान, एसोसिएट प्रोफेसर निगेल क्रॉफर्ड, कनाडा में बीसी प्रांत के प्रांतीय स्वास्थ्य अधिकारी (PHO) डॉ बोनी हेनरी से बात करते हैं। जैसा कि PHO बोनी COVID-19 महामारी के लिए प्रांत की प्रतिक्रिया का नेतृत्व कर रहे हैं। बोनी 2018 की शुरुआत से इस भूमिका में हैं और इससे पहले तीन साल तक डिप्टी पीएचओ थे। वह सार्वजनिक स्वास्थ्य और निवारक चिकित्सा में माहिर हैं, और पाकिस्तान में विश्व स्वास्थ्य संगठन और यूनिसेफ पोलियो उन्मूलन कार्यक्रम और युगांडा में इबोला के प्रकोप के दौरान डब्ल्यूएचओ के साथ काम करने की पृष्ठभूमि है। उनके पास SARS, H1N1 महामारी और BC में ओवरडोज इमरजेंसी के लिए अग्रणी प्रतिक्रिया का अनुभव है। बोनी ब्रिटिश कोलंबिया विश्वविद्यालय, फैकल्टी ऑफ मेडिसिन में एसोसिएट प्रोफेसर हैं और टीकाकरण पर कनाडा की राष्ट्रीय सलाहकार समिति के सदस्य हैं। वह और निगेल निम्नलिखित पर चर्चा करते हैं:

  • बोनी की वर्तमान भूमिका, जो COVID-19 महामारी के लिए BC की प्रतिक्रिया का नेतृत्व कर रही है
  • उसने 2003 के सार्स प्रकोप से क्या सीखा और कैसे इस अनुभव और ज्ञान को वर्तमान महामारी पर लागू किया जा सकता है जैसे संपर्क अनुरेखण का महत्व, प्रकोपों का प्रबंधन और जनता के साथ संवाद करने का महत्व
  • COVID-19 टीके कनाडा में भूमिका निभाएंगे और ऐसी चुनौतियाँ जिनका सामना करने की आवश्यकता होगी जैसे कि रसद, पर्याप्त सुरक्षा प्रोफ़ाइल सुनिश्चित करना, प्राथमिक समूहों को पहले प्रतिरक्षित करना और स्वदेशी समुदायों की रक्षा करना
  • टीकाकरण के बाद प्रतिकूल घटनाओं के लिए निगरानी का महत्वपूर्ण महत्व


आप यहां एपिसोड सुन सकते हैं:

स्प्रेकर - सेब - Spotify 

BBC: Covid vaccine - First 'milestone' vaccine offers 90% protection

Vaccine developers Pfizer and BioNTech have announced preliminary data shows their COVID-19 vaccine is demonstrating 90% effectiveness. The vaccine has been tested on over 43,000 people in six countries (USA, Germany, Brazil, Argentina, South Africa and Turkey). They are planning to apply for emergency approval so the vaccine can be in use by the end of November.

Requiring two doses three weeks apart, the vaccine has been developed using an mRNA platform. Scientists take part of the virus’s genetic code and coat it in a lipid so that it can enter the body’s cells resulting in the production of the coronavirus spike protein, prompting the immune system to produce antibodies and T-cells to kill the infected cells. If the person who has been immunised encounters the virus, the antibodies and T-cells are then activated to fight the virus.

It is not known how effective the vaccine will be in elderly people as yet or how long immunity will last. This vaccine is not without manufacturing and logistical challenges, as mRNA vaccines need to be stored at minus 80 degrees Celsius. To date, no major safety issues have been identified.

Read more about this via the link below:

BBC: Covid vaccine: First 'milestone' vaccine offers 90% protection 


COVID19 Road to a vaccine episode 16: COVID-19 vaccine candidates regulatory process update with Professor Norman Baylor

In episode 16 of our COVID19 Road to a vaccine series, our host, Associate Professor Nigel Crawford speaks once again with Professor Norman Baylor. Professor Baylor is the former Director of the Office of Vaccines Research and Review Center at the U.S. Food and Drug Administration (FDA) and is the President and CEO of Biologics Consulting and current advisor to the WHO.

In this episode they discuss:

  • The recent FDA Vaccines and related biological products advisory committee meeting which was, as is customary, open to the public
  • The huge amount countries like Australia can learn from the transparency of these open forums
  • What vaccine efficacy thresholds are and what they have been set at for COVID-19 vaccine candidates in the USA
  • Including children and special risk groups such as pregnant women in clinical trials
  • Potential for confusion when more than one COVID-19 vaccine becomes available with varying levels of efficacy
  • The ongoing collection of data to monitor vaccine safety and effectiveness
  • Pauses or clinical holds being a normal part of clinical trials
  • The importance of communication from regulatory bodies as COVID-19 vaccines become available


Download the episode at:

स्प्रेकर - सेब - Spotify 

COVID19 Road to a vaccine episode 15: Professor Lynn Gillam

In episode 15, our host, Associate Professor Nigel Crawford, speaks to Professor Lynn Gillam. Lynn is a clinical ethicist who trained in philosophy and bioethics. She is a Professor in the Centre for Health Equity, in the Melbourne School of Population and Global Health at the University of Melbourne; and the Academic Director of The Children’s Bioethics Centre at the Royal Children’s Hospital in Melbourne, Australia. The Children’s Bioethics Centre provides support including ethical decision making for clinicians in relation to patient care issues. Nigel and Lynn will discuss some of the ethical issues raised in the setting of SARS-CoV-2 vaccines, utilising a framework of points raised by Dr John Lantos from the Children’s Mercy Hospital in Kansas City, USA, at the recent Bioethics E-Conference hosted by The Children’s Bioethics Centre:

  • The importance of realising that not doing something or not conducting research is a decision in itself
  • The notion of “too fast can’t be safe” – some steps need to take the time they have always taken, some things can be done more quickly, recognising that if you do nothing, you are allowing harm to happen
  • The role of ethical boards and the way vaccines are developed, i.e. the use of younger, healthier participants in research, not the individuals who are getting the worst disease
  • The involvement of children and elderly people in clinical trials and the key differences in the ethical considerations of this
  • Global equity of access to SARS-CoV-2 vaccines when they become available, who gets them first and how should these decisions be made?
  • The role of Citizens’ Juries in deciding who has priority of access to vaccines in a pandemic situation
  • अनिवार्य टीकाकरण
  • The use of foetal embryonic cell lines in vaccine development


Listen to the episode here:

स्प्रेकर - सेब - Spotify